# AMG 595 First-in-Human in Recurrent Gliomas

> **NCT01475006** · PHASE1 · COMPLETED · sponsor: **Amgen** · enrollment: 32 (actual)

## Conditions studied

- Advanced Malignant Glioma
- Anaplastic Astrocytomas
- Glioblastoma Multiforme

## Interventions

- **DRUG:** AMG 595

## Key facts

- **NCT ID:** NCT01475006
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-02
- **Primary completion:** 2016-04
- **Final completion:** 2016-04
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2016-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01475006

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01475006, "AMG 595 First-in-Human in Recurrent Gliomas". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01475006. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*